Vamorolone
- Generic Name
- Vamorolone
- Brand Names
- Agamree
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28O4
- CAS Number
- 13209-41-1
- Unique Ingredient Identifier
- 8XP29XMB43
- Background
Vamorolone is under investigation in clinical trial NCT03439670 (A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)).
- Indication
Vamorolone is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients ≥2 years of age.
- Associated Conditions
- Duchenne Muscular Dystrophy (DMD)
- Associated Therapies
- -
Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Santhera Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT06689527
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Santhera Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT06649409
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy.
- Conditions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06564974
- Locations
- 🇺🇸
Arkansas Childrens Hospital, Little Rock, Arkansas, United States
🇺🇸University of Massachusetts Memorial Medical Center, North Worcester, Massachusetts, United States
🇺🇸Duke University Medical Center and Childrens Health Center, Durham, North Carolina, United States
A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Santhera Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT05185622
- Locations
- 🇨🇦
Alberta's Children Hospital, Calgary, Alberta, Canada
🇨🇦Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
🇨🇦The Hospital for Sick Children, Toronto, Ontario, Canada
A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05166109
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇮🇹Azienda Ospedale Universita Padova, Padova, Italy
Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy
- Conditions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Santhera Pharmaceuticals
- Registration Number
- NCT03863119
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸University of California Davis, Davis, California, United States
🇺🇸Nemours Children's Hospital, Orlando, Florida, United States
A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT03439670
- Locations
- 🇨🇦
Montreal Children's Hospital, Montréal, Quebec, Canada
🇧🇪Ghent University Hospital, Ghent, Belgium
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.